This report, prepared for CSL Behring, provides our assessment of how the Congressional Budget Office might score legislation which would create the authority for CMS to make explicit add-on payments for IVIG, in both the office and outpatient settings, to cover provider shortfalls between product costs and Average Sales Price (ASP)-based reimbursement rates.  The legislation would also establish separate drug administration payments for home infusion of IVIG.

Full title: Budgetary Effects of Medicare Reimbursement Enhancements for Intravenous Immune Globulin

Use this link http://www.themorancompany.com/index.php?option=com_docman&task=doc_download&gid=5&Itemid=28 to download the report.